STOCK TITAN

Supernus Pharmaceuticals Inc - SUPN STOCK NEWS

Welcome to our dedicated news page for Supernus Pharmaceuticals (Ticker: SUPN), a resource for investors and traders seeking the latest updates and insights on Supernus Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Supernus Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Supernus Pharmaceuticals's position in the market.

Rhea-AI Summary
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) will announce its first-quarter 2024 financial results on May 8, 2024. The company, focused on CNS diseases, will host a conference call with President and CEO Jack Khattar and CFO Tim Dec. The call will include a live webcast accessible on the Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Supernus Pharmaceuticals, Inc. receives a Complete Response Letter (CRL) from the FDA for SPN-830, an investigational apomorphine infusion device for Parkinson's disease. The CRL highlights two areas needing further review - product quality and master file for the infusion device. The Company plans to address these issues and resubmit the NDA for SPN-830.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.67%
Tags
none
-
Rhea-AI Summary
Supernus Pharmaceuticals, Inc. announced CEO Jack Khattar will participate in investor conferences in March 2024. The company focuses on CNS disease treatments. Investors can arrange meetings with management at the conferences, and a webcast of the fireside chat will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
conferences
Rhea-AI Summary
Supernus Pharmaceuticals, Inc. (SUPN) CEO to participate in a fireside chat at the TD Cowen 44th Annual Healthcare Conference. Investors can arrange meetings with management. Live webcast available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
conferences
-
Rhea-AI Summary
Supernus Pharmaceuticals, Inc. reported robust financial results for Q4 2023 and FY 2023, with significant growth in net sales of Qelbree and GOCOVRI. The company also provided optimistic guidance for FY 2024, expecting continued growth and product launches. Various clinical trials and pipeline updates indicate a promising future for the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
-
Rhea-AI Summary
Supernus Pharmaceuticals, Inc. (SUPN) will report financial and business results for Q4 and full year 2023 on February 27, 2024. The conference call hosted by the President and CEO, Jack Khattar, and CFO, Tim Dec, will provide insights into the company's performance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
Rhea-AI Summary
Supernus Pharmaceuticals, Inc. has won a legal battle against Torrent Pharmaceuticals Ltd. and its subsidiary, Torrent Pharma Inc., regarding the infringement of three U.S. patents related to Trokendi XR®. The United States District Court for the District of New Jersey ruled in favor of Supernus, affirming the validity of the patents and the infringement by Torrent. This ruling prevents Torrent from marketing a generic version of Trokendi XR® before the expiration of Supernus' patents, securing the company's intellectual property rights and market exclusivity. Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, expressed satisfaction with the court's decision, emphasizing the significance of protecting their patented products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
none
-
Rhea-AI Summary
SUPN: Supernus Pharmaceuticals Raises Full Year 2023 Earnings Guidance to $95M-$110M, Announces Strong Q3 Financial Results and Positive Qelbree Update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.14%
Tags
-
Rhea-AI Summary
Supernus Pharmaceuticals, Inc. (SUPN) to participate in fireside chat at Jefferies London Healthcare Conference, President and CEO Jack Khattar to speak on November 15, 2023. Investors can arrange meetings with company management. Live webcast available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.42%
Tags
conferences
Rhea-AI Summary
Supernus Pharmaceuticals announces FDA acceptance of resubmission for SPN-830, with a PDUFA date of April 5, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
none
Supernus Pharmaceuticals Inc

Nasdaq:SUPN

SUPN Rankings

SUPN Stock Data

1.66B
47.71M
5.12%
108.06%
8.81%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Rockville

About SUPN

pioneering new medicines in neurology and psychiatry with more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (cns) disorders. in 2013 we launched oxtellar xr® and trokendi xr®, two novel neurology products for the treatment of epilepsy. we are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (adhd) and its coexisting disorders, and depression. we are developing differentiated products by leveraging our proprietary and in-licensed technologies. we use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.